Medicenna Therapeutics (TSX:MDNA) Cash And Cash Equivalents : C$30.00 Mil (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Cash And Cash Equivalents?

Medicenna Therapeutics's quarterly cash and cash equivalents declined from Jun. 2024 (C$35.63 Mil) to Sep. 2024 (C$30.43 Mil) but then stayed the same from Sep. 2024 (C$30.43 Mil) to Dec. 2024 (C$30.00 Mil).

Medicenna Therapeutics's annual cash and cash equivalents increased from Mar. 2022 (C$20.54 Mil) to Mar. 2023 (C$33.60 Mil) but then declined from Mar. 2023 (C$33.60 Mil) to Mar. 2024 (C$16.98 Mil).

Medicenna Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Medicenna Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Cash And Cash Equivalents Chart

Medicenna Therapeutics Annual Data

Trend

Dec15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

22.70

30.38

20.54

33.60

16.98

Medicenna Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															21.76	16.98	35.63	30.43	30.00

Medicenna Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Medicenna Therapeutics (TSX:MDNA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Medicenna Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicenna Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

MDNAF:USA

Address

2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2

Website

https://www.medicenna.com

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

Executives

Albert George Beraldo	Director
Fahar Merchant	10% Security Holder, Director, Senior Officer
Chandra Panchal	Director
Elizabeth Williams	Senior Officer

Medicenna Therapeutics Headlines

No Headlines